Date post: | 17-Dec-2015 |
Category: |
Documents |
Upload: | dinah-pierce |
View: | 213 times |
Download: | 1 times |
Presented at the 2008 International Symposium on Pharmaceuticals in the Home and Environment: Catalysts for Change, November 10-11, 2008 and to be used for this purpose only. Please do not forward
Special Considerations for Unused Drugs Subject to Restricted Distribution Programs
Special Considerations for Unused Drugs Subject to Restricted Distribution Programs
Presented at the 2008 International Symposium on Pharmaceuticals in the Home and Environment: Catalysts for Change, November 10-11, 2008
Colleen ChawlaManager, State Government RelationsCelgene Corporation
Presented at the 2008 International Symposium on Pharmaceuticals in the Home and Environment: Catalysts for Change, November 10-11, 2008 and to be used for this purpose only. Please do not forward
About CelgeneAbout Celgene
• A global biopharmaceutical company dedicated to helping healthcare providers turn incurable blood cancers into chronic, manageable diseases.
• Five FDA-approved products • More than 2,300 employees worldwide• Based in Summit, NJ
Presented at the 2008 International Symposium on Pharmaceuticals in the Home and Environment: Catalysts for Change, November 10-11, 2008 and to be used for this purpose only. Please do not forward
Why is Celgene Interested in the Issue of Unused Pharmaceuticals?Why is Celgene Interested in the Issue of Unused Pharmaceuticals?
• Commitment to patient safety• Drugs are subject to FDA-mandated
restricted distribution programs created by Celgene in cooperation with the FDA and intended to protect patients
• Absent proper precautions, some proposed solutions could circumvent FDA-mandated restricted distribution programs and create serious health risks for patients or others– Drug Collection and Takeback Programs– Drug Repository/Reuse Programs
Presented at the 2008 International Symposium on Pharmaceuticals in the Home and Environment: Catalysts for Change, November 10-11, 2008 and to be used for this purpose only. Please do not forward
What is a Restricted Distribution Program?What is a Restricted Distribution Program?
• ~ 15 drugs are required by the FDA to have Risk Minimization Action Plans (RiskMAPs)*– Strategic safety programs designed to meet
specific goals and objectives in minimizing product risks while preserving its benefits.
• A handful of those meet these goals by using restricted distribution programs
* following the Food and Drug Administration Amendments Act of 2007, referred to as Risk Evaluation and Mitigation Strategies (REMS)
Presented at the 2008 International Symposium on Pharmaceuticals in the Home and Environment: Catalysts for Change, November 10-11, 2008 and to be used for this purpose only. Please do not forward
Risk Management OptionsRisk Management Options
Riskcomm.
Packagingrestrictions
Informedconsents
Manageddistribution
Productwithdrawal
Monitoringadverse events
Labeling Box warnings Medication guides Patient labeling Dear Dr. letters Health advisories Educational forums Posting of papers Sales force outreach
RiskInterventions
Voluntaryefforts
Presented at the 2008 International Symposium on Pharmaceuticals in the Home and Environment: Catalysts for Change, November 10-11, 2008 and to be used for this purpose only. Please do not forward
Two Examples of Restricted Distribution DrugsTwo Examples of Restricted Distribution Drugs
• Thalomid® (thalidomide)– First approved in the US in 1998 for the treatment of certain
conditions associated with Erythema Nodosum Leprosum, and, approved in 2006, for the treatment of patients with newly diagnosed multiple myeloma.
– A known human teratogen.
• Revlimid® (lenalidomide)– Approved in 2005 for certain types of myelodysplastic
syndromes; and, in 2006, for the treatment of multiple myeloma patients who have received at least one prior therapy.
– An analogue of thalidomide.
Presented at the 2008 International Symposium on Pharmaceuticals in the Home and Environment: Catalysts for Change, November 10-11, 2008 and to be used for this purpose only. Please do not forward
Adopted RiskMap ProgramsAdopted RiskMap Programs
S.T.E.P.S.®
System for Thalidomide Education and
Prescribing Safety
Approved in 1998
RevAssist®
RevAssist® program for Revlimid education and
prescribing safety
Approved in 2005
Presented at the 2008 International Symposium on Pharmaceuticals in the Home and Environment: Catalysts for Change, November 10-11, 2008 and to be used for this purpose only. Please do not forward
S.T.E.P.S. RiskMAP OverviewS.T.E.P.S. RiskMAP Overview
• Goal:– Prevent fetal exposure
• Program Components:– Education
• Physicians, nurses and pharmacists• Patients
– Active risk aversion– Controlled distribution
Presented at the 2008 International Symposium on Pharmaceuticals in the Home and Environment: Catalysts for Change, November 10-11, 2008 and to be used for this purpose only. Please do not forward
S.T.E.P.S.S.T.E.P.S.
• System for Thalidomide Education and Prescribing Safety – S.T.E.P.S.®
– Clear product labeling– Required registration of all prescribers, patients, and pharmacists– A patient acknowledgement / informed consent form – Authorization validation prior to dispense– A required telephonic survey for patients and prescribers– Required pregnancy testing in females of childbearing potential – Compliance with measures to prevent pregnancy– Educational brochure and video tape – Patient counseling – Restricted prescriptions– Distribution of Thalomid® from Celgene only to registered
pharmacies
Presented at the 2008 International Symposium on Pharmaceuticals in the Home and Environment: Catalysts for Change, November 10-11, 2008 and to be used for this purpose only. Please do not forward
Patient Return of Unused Thalomid® Also a Part of S.T.E.P.S.®Patient Return of Unused Thalomid® Also a Part of S.T.E.P.S.®
• Patients contact Celgene Customer Care at 1-888-423-5436
• Customer Care gathers information on the drug to be returned and issues Return Authorization
• Customer Care mails a prepaid UPS mailing label to use for return of the drug
• Patient returns the drug via UPS• At the warehouse, returned drug cross-referenced
with Return Authorization • Information logged into database• Returned product incinerated in accordance with
local laws
Presented at the 2008 International Symposium on Pharmaceuticals in the Home and Environment: Catalysts for Change, November 10-11, 2008 and to be used for this purpose only. Please do not forward
State Efforts Targeting Unused DrugsState Efforts Targeting Unused Drugs
• Drug Donation/Repository Programs– Allow individuals or institutions to donate unused
medications so that they may be re-dispensed to patients in need
• Drug Take-back Programs– Provide for the collection of unused medications
for proper disposal
Presented at the 2008 International Symposium on Pharmaceuticals in the Home and Environment: Catalysts for Change, November 10-11, 2008 and to be used for this purpose only. Please do not forward
Drug RepositoriesDrug Repositories
• 28 state programs• Programs differ by state
– Cancer-specific– Drugs eligible for donation– Donating entities– Receiving entities
Presented at the 2008 International Symposium on Pharmaceuticals in the Home and Environment: Catalysts for Change, November 10-11, 2008 and to be used for this purpose only. Please do not forward
States with Drug Donation/Repository ProgramsStates with Drug Donation/Repository Programs
General Drug Donation/Repository Program
Cancer-specific Program
Both General and Cancer-specific Programs
Presented at the 2008 International Symposium on Pharmaceuticals in the Home and Environment: Catalysts for Change, November 10-11, 2008 and to be used for this purpose only. Please do not forward
Drug Take-back ProgramsDrug Take-back Programs
• Iowa and Maine have enacted take-back legislation
• Many other states have considered legislation (CA, MA, IL, NY, OR, PA, VA, WA, WI)
Presented at the 2008 International Symposium on Pharmaceuticals in the Home and Environment: Catalysts for Change, November 10-11, 2008 and to be used for this purpose only. Please do not forward
Why Should Restricted Distribution Drugs be Treated Differently?Why Should Restricted Distribution Drugs be Treated Differently?
• To protect patient safety– In the case of Thalomid® and Revlimid®, no fetal
exposure– Compliance with handling restrictions
• To protect public safety– Ensure safe handling– Avoid diversion
Presented at the 2008 International Symposium on Pharmaceuticals in the Home and Environment: Catalysts for Change, November 10-11, 2008 and to be used for this purpose only. Please do not forward
Why Should Restricted Distribution Drugs be Treated Differently? (cont.)Why Should Restricted Distribution Drugs be Treated Differently? (cont.)
• To ensure adherence to FDA-mandated restricted distribution programs– Designed to protect patients– Deviation compromises patient protections– Restricted distribution programs may provide for
the safe return and disposal of drugs by patients– Utilization of existing return programs allows for
more accurate inventory control
Presented at the 2008 International Symposium on Pharmaceuticals in the Home and Environment: Catalysts for Change, November 10-11, 2008 and to be used for this purpose only. Please do not forward
Why Should Restricted Distribution Drugs be Treated Differently? (cont.)Why Should Restricted Distribution Drugs be Treated Differently? (cont.)
• To avoid preventable exposures that could impact the availability of these drugs for those who need them– Fetal exposure could cause drugs to be pulled
from the market– Patients that rely on these drugs would be denied
access to these therapies– Research on the effectiveness of these drugs for
other diseases would cease
Presented at the 2008 International Symposium on Pharmaceuticals in the Home and Environment: Catalysts for Change, November 10-11, 2008 and to be used for this purpose only. Please do not forward
Issues to Consider for Repositories and Take-back ProgramsIssues to Consider for Repositories and Take-back Programs
• Repositories– Distribution of restricted distribution drugs
without the benefit of education, counseling, and other precautions could pose a significant danger to patients
– Specific prohibition against sharing the drug– Liability for health care practitioners and the state
• Take-back Programs– Unsafe handling could pose a significant threat to
the public health– Prudent to take advantage of existing programs
Presented at the 2008 International Symposium on Pharmaceuticals in the Home and Environment: Catalysts for Change, November 10-11, 2008 and to be used for this purpose only. Please do not forward
Proposed ActionsProposed Actions
• Repositories– Exempt drugs subject to restricted distribution
programs from being donated or re-dispensed through repository programs
• Take-back programs– Direct patients and others to utilize existing drug-
specific return programs when available– Ensure program protocols include proper
handling precautions (i.e., appropriate personal protection devices)
– Ensure disposal methods are consistent with manufacturer-recommended disposal